MacroGenics MGD024-01: A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies
Clinical Trial Grant
Awarded By
MacroGenics, Inc.
Start Date
February 16, 2023
End Date
February 14, 2028
Awarded By
MacroGenics, Inc.
Start Date
February 16, 2023
End Date
February 14, 2028